Sylvie Lorenzen

8PUBLICATIONS
54CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 27, 2026
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial.

Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience

|Jan 17, 2025
Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024.

Tae-Han Kim, Ichiro Uyama, Sun Young Rha

|Nov 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy.

Joseph Tintelnot, Lisa Paschold, Eray Goekkurt

|Apr 13, 2024
HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments.

Magdalena K Scheck, Ralf D Hofheinz, Sylvie Lorenzen

|Mar 06, 2024
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.

Michael Masetti, Salah-Eddin Al-Batran, Thorsten O Goetze

|Nov 14, 2023
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.

Sylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss-Patience

Pageof 2

Frequent Collaborators

5 joint publications

Thomas Jens Ettrich

2 joint publications

Peter Thuss-Patience

2 joint publications

Ralf-Dieter Hofheinz

2 joint publications

Michael Bitzer